MAIO M

Baseline neutrophil and derived neutrophil-to-lymphocyte ratio, either alone, or better combined, are significantly and independently associated with progression-free survival and overall survival of metastatic melanoma patients receiving ipilimumab therapy. These factors may serve as objective, inexpensive markers to help risk-group...

Background: Patients with advanced melanoma are faced with a poor prognosis and, until recently, limited treatment options. Ipilimumab, a novel immunotherapy that blocks cytotoxic T-lymphocyte-associated antigen-4, was the first agent to improve survival of patients with advanced melanoma in a randomised, controlled phase 3 trial. We used data...

Patients with melanoma brain metastases have a poor prognosis and historically have been excluded from clinical trials. The Expanded Access Program (EAP) provided an opportunity to evaluate the feasibility of ipilimumab (3 mg/kg every 3 weeks for four doses) in patients with stage 3 (unresectable) or 4 melanoma and asymptomatic brain...

Background: Retreatment with ipilimumab has been shown to re-establish disease control in some patients with disease progression. Here, we report the efficacy and safety of retreatment with ipilimumab 3mg kg(-1) among patients participating in an expanded access programme in Italy. Methods: Patients who achieved disease control during induction...

No description

No description